Last reviewed · How we verify
Psoriatic Arthritis and Ankylosing Spondylitis
Approved treatments
- Induction- PF-06480605 150 mg SC Q4W · Pfizer
PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Psoriatic Arthritis and Ankylosing Spondylitis patent landscape — cliff calendar, originator estates, attackable patents
- Psoriatic Arthritis and Ankylosing Spondylitis treatment landscape brief
- Psoriatic Arthritis and Ankylosing Spondylitis treatment updates RSS
Frequently asked questions about Psoriatic Arthritis and Ankylosing Spondylitis
What drugs treat Psoriatic Arthritis and Ankylosing Spondylitis?
Tracked treatments include Induction- PF-06480605 150 mg SC Q4W.
What is the treatment for Psoriatic Arthritis and Ankylosing Spondylitis?
Standard treatment for Psoriatic Arthritis and Ankylosing Spondylitis includes Induction- PF-06480605 150 mg SC Q4W. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Psoriatic Arthritis and Ankylosing Spondylitis patent cliff · Psoriatic Arthritis and Ankylosing Spondylitis CI report
- Treatment: Induction- PF-06480605 150 mg SC Q4W · Pfizer
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing